Danaher Corp (NYSE:DHR) on Wednesday reported fourth-quarter 2025 sales of $6.84 billion, up 4.5% year-over-year, beating the consensus of $6.81 billion.
Core revenue increased 2.5% year-over-year, in line with the expected low single digits.
The life science giant reported adjusted earnings of $2.23 per share, beating the consensus of $2.15.
Rainer Blair, President and CEO, on Wednesday stated, “We delivered a strong finish to the year with better-than-expected performance across our portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams’ disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations.”
Operating cash flow was $2.1 billion, and adjusted free cash flow was $1.8 billion.
Danaher’s fourth-quarter adjusted operating profit margin of 28.3% exceeded expectations of around 27%.
Biotechnology sales increased to $2.033 billion compared to $1.87 billion a year ago, with core growth of 6%.
Sales in the Life Sciences segment reached $2.09 billion, a slight jump from $2.03 billion a year ago. Core growth was 0.5%.
Diagnostics showed good momentum across as sales increased from $2.64 billion to $2.72 billion, with core growth of 2%.
Cepheid respiratory revenue was around $500 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.